Clinical Trial: NCT03511664
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Endocyte |
| Information Provided By: | Endocyte |
| Last Update Posted: | 2025-01-13 |
Study Overview
Brief Summary
The primary objective of this study was to compare the two alternate primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) in patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who received 177Lu-PSMA-617 in addition to best supportive/best standard of care (BSC/BSoC) versus patients treated with best supportive/best standard of care alone.
Official Title
Conditions
Intervention / Treatment
- Drug: 177Lu-PSMA-617
- Other: Best supportive/best standard of care
Other Study ID Numbers
- PSMA-617-01
- 2018-000459-41
- CAAA617A12301
- 2018
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Endocyte |
| Information Provided By: | Endocyte |
| Last Update Posted: | 2025-01-13 |
Study Overview
Brief Summary
The primary objective of this study was to compare the two alternate primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) in patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who received 177Lu-PSMA-617 in addition to best supportive/best standard of care (BSC/BSoC) versus patients treated with best supportive/best standard of care alone.
Official Title
Conditions
Intervention / Treatment
- Drug: 177Lu-PSMA-617
- Other: Best supportive/best standard of care
Other Study ID Numbers
- PSMA-617-01
- 2018-000459-41
- CAAA617A12301
- 2018